Fund Holdings — Flagship Pioneering Inc.

Total Portfolio Value
$1.33B
Total Bought
$6.15M
Total Sold
$47.57M
Net Transaction
-$41.42M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2023
▲▼
Q4 2023
▲▼
Change
▲▼
Q3 2023
▲▼
Q4 2023
▲▼
Weight (%)
▲▼
Change
▲▼
Omega Therapeutics Inc29,225,57929,225,579062,83587,9696.64%+25,134
Foghorn Therapeutics Inc(FHTX)12,674,12012,674,120063,37181,7486.17%+18,377
Syros Pharmaceuticals Inc993,8481,293,848+300,0003,92610,0790.76%+6,153
Sana Biotechnology Inc(SANA)25,001,85625,001,856096,757102,0087.70%+5,250
Denali Therapeutics Inc(DNLI)2,619,9682,319,968-300,00054,05049,7873.76%-4,263
Axcella Health Inc1,170,0590-1,170,05912,2150—-12,215
Seres Therapeutics Inc(MCRB)23,117,04523,117,045055,01932,4342.45%-22,584
Evelo Biosciences Inc7,932,6240-7,932,62431,0960—-31,096
Moderna Inc(MRNA)9,666,0389,666,0380998,405961,28772.53%-37,118
Page 1 of 1
Flagship Pioneering Inc. — 13F Holdings — Q4 2023 | TickerTrail